Media stories about American Renal Associates (NYSE:ARA) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. American Renal Associates earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.4570993159771 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

ARA has been the topic of several research reports. Zacks Investment Research raised American Renal Associates from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Thursday, November 16th. SunTrust Banks set a $18.00 price target on American Renal Associates and gave the company a “buy” rating in a report on Sunday, October 15th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $17.00 price target (down previously from $22.00) on shares of American Renal Associates in a report on Tuesday, November 21st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. American Renal Associates presently has a consensus rating of “Buy” and an average target price of $18.25.

American Renal Associates (NYSE:ARA) traded up $0.06 during midday trading on Friday, hitting $18.69. The company’s stock had a trading volume of 99,300 shares, compared to its average volume of 128,925. The company has a market capitalization of $586.11 and a PE ratio of -207.67. American Renal Associates has a 52 week low of $9.91 and a 52 week high of $23.30. The company has a debt-to-equity ratio of 3.57, a current ratio of 1.16 and a quick ratio of 1.13.

American Renal Associates (NYSE:ARA) last posted its quarterly earnings data on Tuesday, November 14th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.03. American Renal Associates had a negative net margin of 2.15% and a positive return on equity of 15.80%. The firm had revenue of $187.71 million for the quarter, compared to analysts’ expectations of $194.60 million. During the same period in the previous year, the company posted $0.28 EPS. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. sell-side analysts predict that American Renal Associates will post 0.56 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact American Renal Associates (ARA) Stock Price” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at

American Renal Associates Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Insider Buying and Selling by Quarter for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with's FREE daily email newsletter.